Healthcare Global Enterprises Limited

rs,

Mumbai - 400051, Maharashtra, India BSE Limited, Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001, Maharashtra, India Dear Sir/Madam, Subject : Investor Presenta

INR 25,454

of LINACs3 100 Operation Theatres2 2.6k+ Capacity Beds2 FY26 Operational and Financial Metrics INR 25,454 Mn Revenue INR 4,711 Mn Adj. EBITDA5 15% YoY 19% YoY 295k Volume4 12% YoY INR 84,261 ARPP4

INR 4,711

n Theatres2 2.6k+ Capacity Beds2 FY26 Operational and Financial Metrics INR 25,454 Mn Revenue INR 4,711 Mn Adj. EBITDA5 15% YoY 19% YoY 295k Volume4 12% YoY INR 84,261 ARPP4 3% YoY 18.5% Adj. EB

15%

eds2 FY26 Operational and Financial Metrics INR 25,454 Mn Revenue INR 4,711 Mn Adj. EBITDA5 15% YoY 19% YoY 295k Volume4 12% YoY INR 84,261 ARPP4 3% YoY 18.5% Adj. EBITDA Margin 68 bps Y

19%

6 Operational and Financial Metrics INR 25,454 Mn Revenue INR 4,711 Mn Adj. EBITDA5 15% YoY 19% YoY 295k Volume4 12% YoY INR 84,261 ARPP4 3% YoY 18.5% Adj. EBITDA Margin 68 bps YoY 14.0%

12%

cial Metrics INR 25,454 Mn Revenue INR 4,711 Mn Adj. EBITDA5 15% YoY 19% YoY 295k Volume4 12% YoY INR 84,261 ARPP4 3% YoY 18.5% Adj. EBITDA Margin 68 bps YoY 14.0% ROCE (Pre-Tax)6 87 bp

INR 84,261

ics INR 25,454 Mn Revenue INR 4,711 Mn Adj. EBITDA5 15% YoY 19% YoY 295k Volume4 12% YoY INR 84,261 ARPP4 3% YoY 18.5% Adj. EBITDA Margin 68 bps YoY 14.0% ROCE (Pre-Tax)6 87 bps YoY Note: (1) ex

3%

Revenue INR 4,711 Mn Adj. EBITDA5 15% YoY 19% YoY 295k Volume4 12% YoY INR 84,261 ARPP4 3% YoY 18.5% Adj. EBITDA Margin 68 bps YoY 14.0% ROCE (Pre-Tax)6 87 bps YoY Note: (1) excludes Ke

18.5%

INR 4,711 Mn Adj. EBITDA5 15% YoY 19% YoY 295k Volume4 12% YoY INR 84,261 ARPP4 3% YoY 18.5% Adj. EBITDA Margin 68 bps YoY 14.0% ROCE (Pre-Tax)6 87 bps YoY Note: (1) excludes Kenya and inc

68 bps

DA5 15% YoY 19% YoY 295k Volume4 12% YoY INR 84,261 ARPP4 3% YoY 18.5% Adj. EBITDA Margin 68 bps YoY 14.0% ROCE (Pre-Tax)6 87 bps YoY Note: (1) excludes Kenya and includes Chennai (2) Includes

14.0%

19% YoY 295k Volume4 12% YoY INR 84,261 ARPP4 3% YoY 18.5% Adj. EBITDA Margin 68 bps YoY 14.0% ROCE (Pre-Tax)6 87 bps YoY Note: (1) excludes Kenya and includes Chennai (2) Includes multispecia

87 bps

12% YoY INR 84,261 ARPP4 3% YoY 18.5% Adj. EBITDA Margin 68 bps YoY 14.0% ROCE (Pre-Tax)6 87 bps YoY Note: (1) excludes Kenya and includes Chennai (2) Includes multispecialty; ~60 beds reclassifi

“Although the Company believes that such forward‐looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met.”

“of LINACs3 100 Operation Theatres2 2.6k+ Capacity Beds2 FY26 Operational and Financial Metrics INR 25,454 Mn Revenue INR 4,711 Mn Adj.”

“Excluding Milann, FY26 revenue grew ~15% YoY, driven by ~12% volume growth and ~3% ARPP improvement.”

“c o m 7 Financial Highlights: FY26 Financial Highlights: FY26 Overall Revenue Adjusted EBITDA1 Adjusted PAT (Post - IND AS) 2 +15% 22,228 25,454 Margin (%) 17.8% 18.5% Margin (%) 2.0% +19% 3,963 4,711 444 +25% 2.2% 557 ROCE3 +87 bps 13% 14% FY25 FY26 FY25 FY26 FY25 FY26 FY25 FY26 Revenue (excl.”

“c o m FY26 Revenue Mix: By Specialty and Payor FY26 Revenue Mix: By Specialty and Payor Non Oncology 11% OP Onco services 16% Specialty Mix Medical Oncology 38% Surgical Oncology 21% Radiation Oncology 14% Government 33% Medical Value Travel 2% Payor Mix Cash + TPA + Corp 65% (1) OP services includes OPD consultation, diagnostics and pharmacy.”

“c o m 9 Region-wise Performance Update: South Region-wise Performance Update: South Revenue Share % (# of IP patients) + 13% + 6% 109,938 124,544 Vizag Vijaywada Ongole Gulburga Hubli Shimonga Bangalore Chennai 39% FY26 Bed share % 39% FY26 Q4FY26 Highlights: • Delivered ~9% YoY revenue growth in Q4 FY26, supported by sustained momentum across key centres, particularly Vizag and Vijayawada.”

“This growth was achieved despite softer contribution from international patients • The cluster remains well-positioned for its next phase of growth, supported by the new North Bengaluru facility and the planned addition of ~25 beds at the Bangalore COE in FY27.”

“Overall Volumes 29,863 31,723 Q4FY25 Q4FY26 FY25 FY26 + 3% 0.1% 79,967 82,169 79,781 79,889 Overall ARPP Q4FY25 Q4FY26 FY25 FY26 (In INR Mn) + 13% 9,950 8,771 Revenue + 9% 2,388 2,607 Q4FY25 Q4FY26 FY25 FY26 www.hcgoncology.com www.hcgoncology.com www .”

“c o m 11 Region-wise Performance Update: East Region-wise Performance Update: East Revenue Share % (# of IP patients) Ranchi Kolkata Cuttack 11% 11% FY26 89% Bed share % 13% FY26 Q4FY26 Highlights: • Delivered ~8% YoY revenue growth in Q4 FY26, supported by strong patient inflows and healthy traction across key centres, particularly Cuttack and Ranchi.”

“No 1 2 Particulars North Bangalore Whitefield FY25 1,221 802 133 41 2,197 FY26 1,804 794 140 147 2,885 Net Debt Items Borrowings(1) Less: Cash & Cash Equivalents(2) Net Debt Capital Leases: Ind AS116 Net Debt (Incl.”

Subject

1

Stock Code

1

Reference

1

Note

1

Subject

Investor Presentation on Annual Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026.

Reference

Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”). This is to inform that the Board of Directors of the Company, at their meeting held today i.e., May 19, 2026, inter alia, has approved the Annual Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026 (“Financial Results”). We enclose herewith the Investor Presentation on the Financial Results of the Company. The above information is also available on the website of the Company and can be accessed at: https://www.hcgoncology.com/ You are requested to take the information on record. Thanking You, For HealthCare Global Enterprises Limited Sunu Manuel Company Secretary and Compliance Officer. Encl: a/a HealthCare Global Enterprises Limited Reg Off: HCG Towers #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bengaluru - 560 027, Karnataka, India Corp Off: #3, G-Floor, Tower Block, Unity B

Note

1. Borrowings : Net of Bank balance held as margin money of ~INR 287mn as at 31st Mar 2026 and ~INR 208 Mn as at 31st Mar 2025. 2. Cash and cash equivalents: Includes investment in mutual funds of ~INR 21mn as at 31st Mar 2026 and ~INR 21mn as at 31st Mar 2025 www.hcgoncology.com www.hcgoncology.com www . h c g o n c o l o g y. c o m www . h c g o n c o l o g y. c o m 14 Net Debt (Pre Ind -AS) HCG continues to demonstrate healthy cash conversion at 75% EBITDA to CFO; Balance sheet has further de-levered to ~1.43x following the rights issue and payment of Vizag acquisition, creating headroom to further invest in growth 2.27x 6,317 FY25 3,471 CFO 1,189 1,696 Capex 1,855 -4,199 Other Incl CFF Maintenance Capex Growth Capex Net Cash Flow from Financing & Others(2) Right Issue Proceeds(3) • EBITDA to CFO of ~75% • Maintenance capex driven by routine medical equipment replacement and infra upgrades • Growth capex spend towards North Bangalore, Ahmedabad COE and Kenya • CFF is mainly towards